News | February 17, 2025
Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Subscribe To Our Newsletter & Stay Updated
